A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

Melanoma Research

Volumn 13, Issue 1, 2003, Pages 97-103

  Mornex, Françoise ^a   Thomas, L ^b   Mohr, P ^c   Hauschild, A ^d   Delaunay, M M ^e   Lesimple, T ^f   Tilgen, W ^g   Bui, B N ^h   Guillot, B ⁱ   Ulrich, J ^j   Bourdin, S ^k   Mousseau, M ^l   Cupissol, D ^m   Bonneterre, M E ⁿ   De Gislain, C ^o   Bensadoun, R J ^p   Clavel, M ^q  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b HÔTEL DIEU   (France)

^c Kreiskrankenhaus   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e HÔPITAL PELLEGRIN   (France)

^f CENTRE EUGÈNE MARQUIS   (France)

^g SAARLAND UNIVERSITY   (Germany)

^h INSTITUT BERGONIÉ   (France)

ⁱ DEPARTMENT OF NEUROLOGY   (France)

^j Institut für Biochemie   (Germany)

^k CENTRE RENÉ GAUDUCHEAU   (France)

^l CHU La Tronche and University   (France)

^m CENTRE VAL D AURELLE   (France)

ⁿ CENTRE OSCAR LAMBRET   (France)

^o CENTRE GEORGES FRANÇOIS LECLERC   (France)

^p CENTRE ANTOINE LACASSAGNE   (France)

^q CENTRE LÉON BÉRARD   (France)

more..

Author keywords

Brain metastases; Fotemustine; Melanoma; Radiotherapy

Indexed keywords

FOTEMUSTINE;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037331446     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200302000-00016     Document Type: Article

References (23)

1. Johnson JD, Young B. Demographics of cerebral metastasis. Neurosurg Clin N Am 1996; 7:337-344.
2. Balch CM, Houghton AN. Diagnosis of metastatic melanoma at distant sites. In: Balch CM, Houghton AN, Milon GW, Sober AJ, Soong SJ, editors. Cutaneous Melanoma. Philadelphia: Lippincott; 1992, pp. 439-467.
3. Presant CA, Bartolucci AA. Prognostic factors in metastatic malignant melanoma. Cancer 1982; 49:2192-2196.
4. Houghton AN, Balch CM. Treatment for advanced melanoma. In: Balch CM, Houghton AN, Milon GW, Sober AJ, Soong SJ, editors. Cutaneous Melanoma. Philadelphia: Lippincott; 1992, pp. 468-497.
5. Gupta G, Robertson AG, Mackie RM. Cerebral metastases of cutaneous melanoma. Br J Cancer 1997; 76:256-259.
6. Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma. Cancer 1980; 45:679-683.
7. Vlock DR, Kirkwood JM, Leutzinger C, Kapp DS, Fisher JJ. High dose fraction radiation therapy for intracranial metastases of malignant melanoma. A comparison with low dose fraction therapy. Cancer 1982; 49:2289-2294.
8. Stridsklev IC, Hagen S, Kleep O. Radiation therapy for cerebral metastases from malignant melanoma. Acta Radiol Oncol 1984; 23:231-235.
9. Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma cerebral metastasis. Review of Roswell Park Memorial Institute experience. Cancer 1984; 53:2550-2552.
10. Kirkwood JM, Houghton A, Peters L, Kian Ang K, Balch CM, Reintgen DS. Cutaneous melanoma. In: Vita VT, Helmann S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 5th edition. Philadelphia: Lippincott-Raven; 1997, pp. 1947-1994.
11. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, et al. Final report of the French multicenter phase II study on the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66:1873-1878.
12. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990; 25:263-266.
13. Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkhany M, et al. Fotemustine in the treatment of cerebral primary tumors and metastases. Cancer Invest 1994; 12:414-420.
14. Kleeberg UR, Engel E, Israels P, Bröcker E, Tilgen W, Kennes C, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC Melanoma Cooperative Group (MCG). Melanoma Res 1995; 5:195-200.
15. Schallreuter KU, Wenzel E, Brasson FW, Berger J, Breitbart EW, Teichmann W. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991; 29:85-87.
16. Calabresi E, Aapro M, Becquart D, Dirix L, Wils J, Ardizzoni A, et al. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 1991; 2:377-378.
17. Ulrich J, Gedemann G, Gollnick H. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation. J Neuro Oncol 1999; 43:173-178.
18. Bröcker EB, Bohndorf W, Kämpgen E, Treka J, Messer P, Tilgen W, et al. Fotemustine given simultaneously with total cerebral irradiation in multiple cerebral metastases of malignant melanoma: report on a pilot study. Melanoma Res 1996; 6:399-401.
19. Diener-West M, Dobbins TW, Phillips TL, Nelson DF. Identification of an optimal subgroup for treatment evaluation of patients with cerebral metastases using RTOG study 7916. Int J Radiat Oncol 1989; 16:669-673.
20. Stevens G, Firth I, Coates A. Cerebral metastases from malignant melanoma. Radiother Oncol 1992; 23:185-191.
21. Willner J, Bohndorf W. ZNS-Metastasen beim malignen Melanom. Strahlenther Onkol 1995; 171:165-173.
22. Balch CM, Soong SJ, Vreist MM, Carthy WM. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milon GW, Sober AJ, Soong SJ, editors. Cutaneous Melanoma. Philadelphia: Lippincott; 1992, pp. 165-187.
23. Sampson JH, Carter JH, Friedman AH, Seigler HF. Demographics, prognosis and therapy in 702 patients with cerebral metastases from malignant melanoma. J Neurosurg 1998; 88:11-20.